SFXN5 and breast cancer: Moreover, we found that 29 SFXN5 CpG sites (Figure 3e), of which 9 CpG sites (5′-UTR-S_Shelf-cg06573254 and TSS200-Island-cg17647431) were significantly associated with the prognosis of BC patients (Table 5).